APA

Dooley K. E., Savic R. M., Park J., Cramer Y., Hafner R., Hogg E., Janik J., Marzinke M. A., Patterson K., Benson C. A., Hovind L., Dorman S. E. & Haas D. W. (20160216). Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. : Antimicrobial agents and chemotherapy.

Chicago

Dooley Kelly E, Savic Radojka M, Park Jeong-Gun, Cramer Yoninah, Hafner Richard, Hogg Evelyn, Janik Jennifer, Marzinke Mark A, Patterson Kristine, Benson Constance A, Hovind Laura, Dorman Susan E and Haas David W. 20160216. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. : Antimicrobial agents and chemotherapy.

Harvard

Dooley K. E., Savic R. M., Park J., Cramer Y., Hafner R., Hogg E., Janik J., Marzinke M. A., Patterson K., Benson C. A., Hovind L., Dorman S. E. and Haas D. W. (20160216). Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. : Antimicrobial agents and chemotherapy.

MLA

Dooley Kelly E, Savic Radojka M, Park Jeong-Gun, Cramer Yoninah, Hafner Richard, Hogg Evelyn, Janik Jennifer, Marzinke Mark A, Patterson Kristine, Benson Constance A, Hovind Laura, Dorman Susan E and Haas David W. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. : Antimicrobial agents and chemotherapy. 20160216.